pp 2-33: Experimental procedures for compounds 11-13, 9b,d, 9e, 10a-e, 17, 19a,b, 20a-e, 21b-h, 22a-c, 22e, 24b,d,f,g, 25b,d,f,g, 26a-d, 26f,g, 27a-d, 27f,g.
S3
Hz, 1H, pyridine C-H); and 4-chloro-5-nitropyridin-2-amine (0.080 g, 12%): 1 H-NMR (500 MHz, DMSO-d 6 ) 6.58 (s, 1H, pyridine C-H), 7.58 (s, 2H, NH 2 ), 8.79 (s, 1H, pyridine C-H).
5-Bromo-4-chloro-3-nitropyridin-2-amine (13)
4-Chloro-3-nitropyridin-2-amine (0.10 g, 0.58 mmol) was dissolved in dry acetonitrile (20 mL) . N-Bromosuccinimide (0.124 g, 0.70 mmol) was added to the stirred solution, and the reaction mixture heated at 80 o C for 1 h. Volatiles were removed in vacuo and the residue purified by silica column chromatography (elution with DCM) to provide the product as a pale brown powder (0.125 g, 85%). 1 H-NMR (500 MHz, DMSO-d 6 ) 7.35 (s, 2H, NH 2 ), 8.41 (s, 1H, 6-H) .
4,5-Dichloro-3-nitropyridin-2-amine (12)
4-Chloro-3-nitropyridin-2-amine (0.10 g, 0.58 mmol) was dissolved in dry acetonitrile (20 mL) . N-Chlorosuccinimide (0.094 g, 0.70 mmol) was added to the stirred solution, and the reaction mixture was heated at 80 o C for 1 h. Volatiles were removed in vacuo and the residue purified by silica column chromatography (elution with DCM) to provide the product as a pale brown powder (0.125 g, 85%). 1 H-NMR (500 MHz, DMSO-d 6 ) 7.35 (s, 2H, NH 2 ), 8.36 (s, 1H, 6-H) .
4-(4-Acetylpiperazin-1-yl)benzaldehyde (9b)
To a solution of tert-butyl 4-(4-formylphenyl)piperazine-1-carboxylate (0.102 g, 0.35 mmol) in dichloromethane (2.5 mL) was added trifluoroacetic acid (1.0 mL). The reaction mixture S4 was stirred at room temperature for 1.5 h before being concentrated in vacuo. The resulting residue was dissolved in anhydrous dichloromethane (3.5 mL) under argon, and the solution was cooled to 0 o C. A solution of acetyl chloride (0.050 g, 0.64 mmol) in anhydrous dichlorometane (1 mL) was then slowly added followed by diisopropylethylamine (0.18 mL, 1.05 mmol). The clear solution was stirred for 4 h under argon and allowed to warm to room temperature. The solvents were removed in vacuo, the residue was absorbed on silica gel and placed on a 10 g isolute silica column. Elution with a gradient of ethyl acetate in dichloromethane (20 to 50%) afforded the desired product as a white solid (0.052 g, 64%). 
b]pyridin-2-yl)phenyl)piperazin-1-yl)ethanone (10b)
To a mixture of 5-bromo-4-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3-nitropyridin-2-amine (0.056 g, 0.14 mmol) and EtOH (6 mL) was added 4-(4-acetylpiperazin-1yl)benzaldehyde (0.042 g, 0.18 mmol) followed by a freshly prepared aqueous solution of Na 2 S 2 O 4 (1M; 0.56 mL, 0.56 mmol). The reaction mixture was stirred at 80 o C for 20 h, then allowed to cool to room temperature and concentrated in vacuo. The residue was absorbed on silica gel, and the free-running powder was placed on a 10 g isolute silica column and eluted with a gradient of methanol (0 to 8%) in ethyl acetate / dichloromethane (v:v; 1:1). After trituration with diethyl ether, the precipitate was collected by filtration and washed with water and diethyl ether to afford the title compound as a pale yellow solid (0.028 g, 35%). 1 H-S5 NMR (500 MHz, DMSO-d 6 ) 2.05 (s, 3H, COCH 3 ), 2.40 (s, 3H, isoxazole 5-CH 3 ), 2.62 (br s, 4H), 3.25 (br t, J = 5.0 Hz, 2H), 3.31 (m obscured by water peak), 3.59 (br s, 6H), and 3.62 (br s, 4H) (piperazine C-H and N-CH 2 -isoxazole), 6.25 (s, 1H, 4-H isoxazole), 7.08 (d, J = 9.0 Hz, 2H) and 8.04 (d, J = 8.9 Hz, 2H) (2,6-C 6 H 4 and 3,5-C 6 H 4 ), 8.18 (s, 1H, imidazo[4,5b] pyridine 5-H), 13.27 (br s, 1H, imidazo[4,5-b] 
4-(4-(6-Bromo-7-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3H-imidazo[4,5b]pyridin-2-yl)phenyl)morpholine (10a)
To a mixture of 5-bromo-4-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3-nitropyridin-2-amine (0.060 g, 0.15 mmol) and EtOH (6 mL) was added 4-(morpholin-4-yl)benzaldehyde (0.036 g, 0.19 mmol) followed by a freshly prepared aqueous solution of Na 2 S 2 O 4 (1M; 0.6 mL, 0.6 mmol). The reaction mixture was stirred at 80 o C for 18 h, then allowed to cool to room temperature and concentrated in vacuo. The residue was absorbed on silica gel, and the free-running powder was placed on a 10 g isolute silica column. Elution with a gradient of methanol (0 to 4%) in ethyl acetate / dichloromethane (v:v; 1:1) afforded the title compound as a white solid after trituration with diethyl ether (0.031 g, 39%). 1 H-NMR (500 MHz, DMSO-d 6 ) 2.40 (s, 3H, isoxazole 5-CH 3 ), 2.62 (br s, 4H), 3.24 (br t, J = 4.8 Hz, 4H), 3.62 (br t, J = 4.5 Hz, 4H) and 3.75 (t, J = 5.0 Hz, 4H) (piperazine N-CH and morpholine CH), 3.59 (s, 2H, N-CH 2 -isoxazole), 6.25 (s, 1H, 4-H isoxazole), 7.08 (d, J = 9.0 Hz, 2H) and 8.04 (d, J = 8.9 Hz, 2H) (2,6-C 6 H 4 and 3,5-C 6 H 4 ), 8.18 (s, 1H, imidazo[4,5-b] pyridine 5-H), 13.27 (br s, 1H, imidazo[4,5-b] 
4-(4-(2-Methoxyethyl)piperazin-1-yl)benzaldehyde (9d)
To a mixture of 4-bromobenzylaldehyde diethyl acetal (0.518 g, 2.0 mmol) and anhydrous toluene (4 mL) was added 1-(2-methoxyethyl)piperazine (0.345 g, 2.4 mmol) followed by Pd 2 (dba) 3 (0.018 g, 0.02 mmol), racemic BINAP (0.037 g, 0.06 mmol) and NaO t Bu (0.326 g, 3.4 mmol). The reaction mixture was placed into an oil bath preheated to 100 o C and stirred at this temperature for 7.5 h under argon, then allowed to cool to room temperature. Aqueous HCl (1M; 10 mL) was added, the mixture was vigorously stirred for 2.5 h, then the pH adjusted to 13 with aqueous NaOH and extracted with ethyl acetate (3 x 40 mL). The combined organics were dried (Na 2 SO 4 ), concentrated in vacuo and the residue absorbed on silica gel and placed on a 20 g isolute column. Elution with a gradient of methanol (0 to 4%) in ethyl acetate / dichloromethane (v/v; 1:1) afforded the title compound as an oil (0.130 g, 26%). 1 H-NMR (500 MHz, DMSO-d 6 ) 2.56 (m, 6H, piperazine C-H and CH 2 CH 2 OMe), 3.26 (s, 3H, OMe), 3.38 (t, J = 5.0 Hz, 4H, piperazine C-H), 3.48 (t, J = 5.8 Hz, 2H, CH 2 OMe), 7.04 (d, J = 8.8 Hz, 2H) and 7.71 (d , J = 8.8 Hz, 2H) (2,6-C 6 H 4 and 3,5-C 6 H 4 ), 9.72 (s, 1H, CHO); LC -MS (ESI, m/z): Rt = 0.95 min -249 (M+H) + .
3-((4-(6-Bromo-2-(4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)-3H-imidazo[4,5b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole (10d)
To a mixture of 5-bromo-4-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3-nitropyridin-2-amine (0.052 g, 0.13 mmol) and EtOH (6.0 mL) was added 4-(4-(2-S7 methoxyethyl)piperazin-1-yl)benzaldehyde (0.042 g, 0.17 mmol) followed by a freshly prepared aqueous solution of Na 2 S 2 O 4 (1M; 0.50 mL, 0.50 mmol). The reaction mixture was stirred at 80 o C for 20 h, then allowed to cool to room temperature and concentrated in vacuo.
The residue was absorbed on silica gel, and placed on a 10 g isolute silica column which was eluted with dichloromethane and then a gradient of methanol (2 to 7%) in ethyl acetate / dichloromethane (v:v; 1:1). Fractions containing the product were combined and concentrated in vacuo. The resulting solid residue was triturated with diethyl ether, and the title compound was isolated as a white solid by filtration and washed with diethyl ether (2 x 7 mL), water (3 x 2 mL), and diethyl ether (3 x 4 mL) (0.022 g, 25%). 1 H-NMR (500 MHz, DMSO-d 6 ) 2.40 (s, 3H, isoxazole 5-CH 3 ), 2.52 (t, J = 5.7 Hz, 2H, CH 2 CH 2 OMe), 2.56 (br s, 4H, piperazine C-H), 2.62 (br s, 4H, piperazine C-H), 3.25 (m, 7H, piperazine C-H and OMe), 3.47 (t, J = 5.7 Hz, 2H, CH 2 CH 2 OMe), 3.59 (s, 2H, N-CH 2 -isoxazole) 3.62 (br t, J = 4.2 Hz, 4H, piperazine C-H), 6.25 (s, 1H, isoxazole 4-H), 7.05 (d, J = 8.9 Hz, 2H) and 8.02 (d, J = 8.9 Hz, 2H) (2,6-C 6 H 4 and 3,5-C 6 H 4 ), 8.17 (s, 1H, imidazo[4,5-b] pyridine 5-H), 13.25 (br s, 1H, imidazo[4,5-b] 
(S)-tert-Butyl 3,4-dimethylpiperazine-1-carboxylate (17)
To a solution of (S)-tert-butyl-3-methylpiperazine-1-carboxylate (349 mg, 1.74 mmol) in MeOH/THF (15 mL each) was added formaldehyde 33% in H 2 O (471 µL, 5.23 mmol) followed by Na(OAc) 3 BH (369 mg, 1.74 mmol). The reaction was stirred for 18 h before being concentrated in vacuo and dry loaded onto silica. Purification was accomplished by flash chromatography on silica gel (3 x 11) eluting with MeOH/CH 2 Cl 2 (10-20%) to yield the S8 title compound (352 mg, 94%). 1 H-NMR (500 MHz, CDCl 3 ) 1.02 (d, J = 6.2 Hz, 3H, CHCH 3 ), 1.43 (s, 9H, -C(CH 3 ) 3 ), 2.00 (dqd, J = 9.8, 6.2, 3.3 Hz, 1H, CHCH 3 ), 2.13 (td, J = 11.5, 3.4 Hz, 1H, CH 2 ), 2.26 (s, 3H, NCH 3 ), 2.58 (br s, 1H, CH 2 ), 2.69 (app d, J = 11.5 Hz, 1H, CH 2 ), 2.99 (t, J = 11.5 Hz, 1H, -CH 2 ), 3.93-3.68 (m, 2H, CH 2 ); LC -MS (ESI, m/z): Rt = 1.20 min -159 (M − t Bu) + .
(S)-4-(3,4-Dimethylpiperazin-1-yl)benzaldehyde (9e)
To a solution of (S)-tert-butyl-3,4-dimethylpiperazine-1-carboxylate (324 mg, 1.51 mmol) in CH 2 Cl 2 (40 mL) was added TFA (4.00 mL, 54.0 mmol) and the solution was stirred at room temperature for 2 h. The reaction was concentrated in vacuo, azeotroping with toluene (x2), to give a yellow oil. The residue was dissolved in DMSO (3.0 mL) and DIPEA (1.10 mL, 6.04 mmol) was added followed by 4-fluorobenzaldehyde (194 µL, 1.81 mmol). The solution was stirred at 120 °C for 2 h. On cooling the reaction was partitioned between EtOAc/H 2 O (100 mL), the separated organic layer was washed with H 2 O (100 mL), brine (50 mL), dried over MgSO 4 , filtered and concentrated in vacuo to give a crude brown oil.
Purification was accomplished by flash chromatography on silica gel (3 x 12) eluting with MeOH/CH 2 Cl 2 (5%) to yield the title compound (121 mg, 0.550 mmol, 37%) as a yellow oil. 1 H-NMR (500 MHz, CDCl 3 ) 1.13 (d, J = 6.2 Hz, 3H, CHCH 3 ), 2.21 (dqd, J = 9.6, 6.2, 3.2 Hz, 1H, CH 2 ), 2.32 (s, 3H, NCH 3 ), 2.35 (td, J = 11.6, 3.4 Hz, 1H, CH 2 ), 2.70 (dd, J = 12.4, 10.2 Hz, 1H, CH 2 ), 2.88 (td, J = 11.6, 2.9 Hz, 1H, CH 2 ), 3.08 (td, J = 11.9, 3.2 Hz, 1H, CH 2 ), 3.65 (ddd, J = 12.4, 3.0, 2.1 Hz, 1H, CH 2 ), 3.73 (dq, J = 12.4, 2.8 Hz, 1H, CH 2 ), 6.88 (d, J = 8.9 Hz, 2H, CH ar ), 7.72 (d, J = 8.9 Hz, 2H, CH ar ), 9.76 (s, 1H, CH ald 
3-Fluoro-4-(4-methylpiperazin-1-yl)benzaldehyde (19a)
A solution of 3,4-difluorobenzaldehyde (0.5g, 3.52 mmol), N-methylpiperazine dihydrochloride (0.60 g, 3.52 mmol) and diisopropylethylamine (1.80 g, 14 mmol) in dimethylsulfoxide (10 mL) was heated at 120 o C for 2 h. The reaction mixture was then cooled to room temperature and partitioned between water (100 mL) and chloroform (60 S10 mL). The aqueous layer was further extracted with ethyl acetate; the organic solutions were combined, dried and concentrated. The crude product was purified by silica column chromatography ( 1 to 5% methanol in chloroform) to give 0.71 g of the desired product (91%). 1 H NMR (500MHz, CDCl 3 ) 2.37 (s, 3 H, NCH 3 ), 2.62 (t, J = 5.1 Hz, 4H, NCH 2 ), 3.31 
3-((4-(6-Chloro-2-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole (20a)
To a mixture of 5-chloro-4-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3-nitropyridin-2-amine (0.07 g, 0.198 mmol) and EtOH (10mL) was added 3-fluoro-4-(4-methylpiperazin-1yl)benzaldehyde (0.051 g, 0.23 mmol) followed by a freshly prepared aqueous solution of Na 2 S 2 O 4 (1M; 0.6 mL, 0.6 mmol). The reaction mixture was heated at reflux for 24 h, then allowed to cool to room temperature and concentrated in vacuo. The residue was taken up in chloroform and 10% aqueous sodium bicarbonate. The aqueous layer was further extracted with dichloromethane and the combined organic solutions dried and concentrated. The crude product was purified by silica column chromatography eluting with 2 to 10% methanol in dichloromethane. The pure fractions provided 55 mg of product (53%). 1 H-NMR (500 MHz, 
2-Fluoro-4-(4-methylpiperazin-1-yl)benzaldehyde (19b)
A solution of 2,4-difluorobenzaldehyde (0.50 g, 3.52 mmol), N-methylpiperazine dihydrochloride (0.6 g, 3.52 mmol) and diisopropylethylamine (1.8 g, 14.0 mmol) in dimethylsulfoxide (10 mL) was heated at 120 o C for 2 h. It was then cooled to room temperature and partitioned between water (100 mL) and chloroform (60 mL). The aqueous layer was further extracted with ethyl acetate; the organic solutions were combined, dried and concentrated. The crude was purified by silica column chromatography (1 to 5% methanol in chloroform) to give 0.7 g of product (85%). 1 H NMR (500MHz, CDCl 3 ) 2.37 (s, 3 H, NCH 3 ), 2.57 (br s, 4H, NCH 2 ), 3.40 (t, J = 5.2 Hz, 4H, NCH 2 ), 6.45 (dd, J = 14.5, 2.4 Hz, 1H, ArH), 6.64 (dd, J = 8.9, 2.6 Hz, 1H, ArH), 7.70 (t, J = 8.9 Hz, 1H, ArH), 10.06 (s, 1 H, CHO); LC -MS (ESI, m/z): Rt = 1.00 min-223 (M+H) + .
3-((4-(6-chloro-2-(2-fluoro-4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-

7-yl)piperazin-1-yl)methyl)-5-methylisoxazole (20b)
To a mixture of 5-chloro-4-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3-nitropyridin-2-amine (0.1 g, 0.28 mmol) and EtOH (10 mL) was added 2-fluoro-4-(4-methylpiperazin-1yl)benzaldehyde (0.071 g, 0.32 mmol) followed by a freshly prepared aqueous solution of Na 2 S 2 O 4 (1M; 0.9 mL, 0.9 mmol). The reaction mixture was heated at reflux for 24 h, then allowed to cool to room temperature and concentrated in vacuo. The residue was taken up in chloroform and 10% aqueous sodium bicarbonate. The aqueous layer was further extracted S12 with dichloromethane and the combined organic solutions dried and concentrated. The crude product was purified by silica column chromatography eluting with 3 to 10% methanol in chloroform. The pure fractions provided 40 mg of product (27%). 1 H-NMR (500 MHz, DMSO-d 6 ) 2.23 (s, 3H, piperazine N-Me), 2.40 (s, 3H, isoxazole 5-CH 3 ), 2.44 (t, J = 4.9 Hz, 4H, piperazine NCH 2 ), 2.62 (br s, 4H, piperazine NCH 2 ), 3.58 (s, 2H, N-CH 2 -isoxazole), 3.67 (br s, 4H, piperazine NCH 2 ), 6.24 (s, 1H, 4-H isoxazole), 6.92 -6.86 (m, 2H, ArH) 
2-(3-(6-Chloro-7-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3H-imidazo[4,5b]pyridin-2-yl)phenoxy)-N,N-dimethylethanamine (20c)
To a mixture of 5-chloro-4-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3nitropyridin-2-amine (0.054 g, 0.15 mmol) and EtOH (10 mL) was added 3-(2-(dimethylamino)ethoxy)benzaldehyde (0.035 g, 0.18 mmol) followed by a freshly prepared aqueous solution of Na 2 S 2 O 4 (1M; 0.45 mL, 0.45 mmol). The reaction mixture was heated at reflux for 24 h, then allowed to cool to room temperature and concentrated in vacuo. The residue was taken up in chloroform and 10% bicarbonate. The aqueous layer was further extracted with dichloromethane and the combined organic solutions dried and concentrated.
The crude product was purified on an SCX ion-exchange column eluting first with 5% methanol in dichloromethane followed by 1M ammonia in methanol. The pure fractions provided 50 mg of product (66 %). 1 H-NMR (500 MHz, DMSO-d 6 ) 2.28 (s, 6H, NMe 2 ), 2.40 (s, 3 H, isoxazole 5-CH 3 ), 2.64 (br s, 4H, piperazine NCH 2 ), 2.70 (t, J = 5.7 Hz, 2H, CH 2 NMe 2 ), 3.60 (s, 2 H, CH 2 -isoxazole), 3.71 (br s, 4H, piperazine NCH 2 ), 4.15 (t, J = 5.7 S13 Hz, 2H, ArOCH 2 ), 6.24 (s, 1H, 4-H isoxazole), 7.09 -7.07 (m , 1H, ArH), 7.46 -7.43 (m, 1H, ArH), 7.78 -7.75 (m, 2H, ArH), 8.11 (s, 1H, imidazo[4,5-b] 
4-(3-(6-Chloro-7-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3H-imidazo[4,5b]pyridin-2-yl)benzyl)morpholine (20e)
To a mixture of 5-chloro-4-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3-nitropyridin-2-amine (0.043 g, 0.12 mmol) and EtOH (5.0 mL) was added 3-(morpholinomethyl)benzaldehyde (0.031 g, 0.15 mmol) followed by a freshly prepared aqueous solution of Na 2 S 2 O 4 (1M; 0.46 mL, 0.46 mmol). The reaction mixture was stirred at 80 o C for 20 h, then allowed to cool to room temperature and concentrated in vacuo. The residue was absorbed on silica gel, and placed on a 10 g isolute silica column. Elution with a gradient of methanol (0 to 6%) in ethyl acetate / dichloromethane (v:v; 1:1) afforded the title compound as a yellow solid after trituration with diethyl ether (0.003 g, 5%). 
6-Chloro-2-(3-dimethylaminomethyl)phenyl-7-(4-(5-methylisoxazol-3ylmethyl)piperazin-1-yl)-imidazo[4,5-b]pyridine (20d)
To 3-bromomethylbenzaldehyde (124 mg, 0.62 mmol) was added a 2M solution of dimethylamine in THF (1.5 mL, 3.0 mmol). The reaction was stirred at 20 o C for 1.75 h. The reaction was added to water (10 mL) and the product extracted with ethyl acetate (3 x 5 mL).
The combined extracts were washed with brine, dried (Na 2 SO 4 ) and evaporated to leave 3dimethylaminomethylbenzaldehyde (105 mg 
3-((4-(6-Chloro-2-(1-methyl-1H-imidazol-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-
1-yl)methyl)-5-methylisoxazole (21b)
To a mixture of 5-chloro-4-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3-nitropyridin-2-amine (0.06 g, 0.17 mmol) and EtOH (10 mL) was added 1-methyl-1H-imidazole-2carbaldehyde (0.022 g, 0.20 mmol) followed by a freshly prepared aqueous solution of Na 2 S 2 O 4 (1M; 0.5 mL, 0.5 mmol). The reaction mixture was heated at reflux for 24 h, then allowed to cool to room temperature and concentrated in vacuo. The residue was taken up in chloroform and 10% aqueous sodium bicarbonate. The aqueous layer was further extracted with dichloromethane and the combined organic solutions dried and concentrated in vacuo.
The crude product was purified by silica column chromatography eluting with 1 to 5% methanol in dichloromethane. The pure fractions provided 50 mg of product (71%). 
3-((4-(6-Chloro-2-(furan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5methylisoxazole (21c)
To a mixture of 5-chloro-4-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3-nitropyridin-2-amine (0.058 g, 0.164 mmol) and EtOH (10 mL) was added furan-3-carbaldehyde (0.019 g, 0.2 mmol) followed by a freshly prepared aqueous solution of Na 2 S 2 O 4 (1M; 0.45 mL, 0.45 S16 mmol). The reaction mixture was heated at reflux for 24 h, then allowed to cool to room temperature and concentrated in vacuo. The residue was taken up in chloroform and 10% aqueous sodium bicarbonate. The aqueous layer was further extracted with dichloromethane and the combined organic solutions dried and concentrated in vacuo. The crude product was purified by silica column chromatography eluting with 1 to 3% methanol in dichloromethane.
The pure fractions provided 45 mg of product (69% 
3-((4-(6-Bromo-2-(2,5-dimethyloxazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1yl)methyl)-5-methylisoxazole (21d)
To a mixture of 5-bromo-4-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3-nitropyridin-2-amine (0.1 g, 0.25 mmol) and EtOH (15 mL) was added 2,5-dimethyloxazole-4carbaldehyde (30 mg, 0.32 mmol) followed by a freshly prepared aqueous solution of Na 2 S 2 O 4 (1M; 1.0 mL, 1.0 mmol). The reaction mixture was heated at reflux for 24 h, then allowed to cool to room temperature and concentrated in vacuo. The residue was taken up in chloroform and 10% aqueous sodium bicarbonate. The aqueous layer was further extracted with dichloromethane and the combined organic solutions dried and concentrated. Ether was added to the residue and a pale white powder precipitated; this was filtered and dried (45 mg). The product was purified on a SCX ion-exchange column to provide the title compound S17 as an off-white powder after trituration with ether (30 mg, 25% 
3-((4-(6-Chloro-2-(5-methylisoxazol-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1yl)methyl)-5-methylisoxazole (21e)
To a mixture of 5-chloro-4-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3-nitropyridin-2-amine (0.055 g, 0.156 mmol) and EtOH (10 mL) was added 5-methylisoxazole-3carbaldehyde (0.02 g, 0.18 mmol) followed by a freshly prepared aqueous solution of Na 2 S 2 O 4 (1M; 0.5 mL, 0.5 mmol). The reaction mixture was heated at reflux for 24 h, then allowed to cool to room temperature and concentrated in vacuo. The residue was taken up in chloroform and 10% aqueous sodium bicarbonate in vacuo. The aqueous layer was further extracted with dichloromethane and the combined organic solutions dried and concentrated.
The crude product was purified by silica column chromatography eluting with 1 to 5% methanol in dichloromethane. The pure fractions provided 34 mg of product (53% 3-((4-(6-Chloro-2-(1-methyl-1H-pyrazol-3-yl 4-(6-Bromo-2-(1,2,3-thiadiazol-4-yl) -3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-
3-((
yl)methyl)-5-methylisoxazole (21f)
To a mixture of 5-bromo-4-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3-nitropyridin-2-amine (0.052 g, 0.131 mmol) and EtOH (10 mL) was added 1,2,3-thiadiazole-4carbaldehyde (0.018g, 0.16 mmol) followed by a freshly prepared aqueous solution of S19 Na 2 S 2 O 4 (1M; 0.4 mL, 0.4 mmol). The reaction mixture was heated at reflux for 24 h, then allowed to cool to room temperature and concentrated in vacuo. The residue was taken up in chloroform and 10% aqueous sodium bicarbonate. The aqueous layer was further extracted with dichloromethane and the combined organic solutions dried and concentrated in vacuo.
The crude product was purified on a silica column eluting with 1 to 5% methanol in dichloromethane. The pure fractions provided 30 mg of product (50%). 4-(6-Chloro-2-(1-ethyl-1H-pyrazol-4-yl 
3-((
3-((4-(6-Chloro-2-(1-isopropyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7yl)piperazin-1-yl)methyl)-5-methylisoxazole (22b)
To a solution of 5-chloro-4-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3-nitropyridin-2-amine (80.0 mg, 0.230 mmol) and 1-isopropyl-1H-pyrazole-4-carbaldehyde (33.2 mg, 0.240 mmol) in EtOH (5.5 mL) was added 1M aqueous Na 2 S 2 O 4 (0.920 mL, 0.920 mmol, 4-(6-Chloro-2-(1-(2,2-difluoroethyl 4-(6-Chloro-2-(3-cyclopropyl-1-methyl-1H-pyrazol-4-yl 
3-((
5-Chloro-4-(4-((4-methyl-1,2,5-oxadiazol-3-yl)methyl)piperazin-1-yl)-3-nitropyridin-2amine (26a)
To a solution of 3-methyl-4-(piperazin-1-ylmethyl)-1,2,5-oxadiazole (114 mg, 0.624 mmol) and 2-amino-3-nitro-4,5-dichloropyridine (150 mg, 0.594 mmol) in iPrOH (4.3 mL) was added DIPEA (466 µl, 2.67 mmol). The solution was stirred at 50 °C for 14½ hrs. On 
3-((4-(6-Chloro-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7yl)piperazin-1-yl)methyl)-4-methyl-1,2,5-oxadiazole (27a)
To a solution of 5-chloro-4-(4-((4-methyl-1,2,5-oxadiazol-3-yl)methyl)piperazin-1-yl)-3- 4-((1,2,4-oxadiazol-3-yl) 
tert-Butyl
methyl)piperazine-1-carboxylate (24b)
To a solution of Boc-piperazine (571 mg, 3.07 mmol) and 3-(chloromethyl)-1,2,4-oxadiazole (400 mg, 3.37 mmol) in CH 2 Cl 2 (30 mL) was added triethylamine (1.70 mL, 12.3 mmol) .
The reaction was stirred for 22 h at 50 °C before being concentrated in vacuo to give a crude oily white solid. Purification was accomplished by flash chromatography on silica gel (4 x 12) eluting with MeOH/CH 2 Cl 2 (5%) to yield the title compound (555 mg, 67%) as a white (4-((1,2,4-Oxadiazol-3-yl) 
4-
methyl)piperazin-1-yl)-5-chloro-3-nitropyridin-2-amine (26b)
To a solution of tert-butyl 4-((1,2,4-oxadiazol-3-yl)methyl)piperazine-1-carboxylate (213 mg, 0.790 mmol) in CH 2 Cl 2 (18 mL) was added TFA (1.8 mL, 23.8 mmol) and the solution was stirred at room temperature for 1½ h. The reaction was concentrated in vacuo, azeotroping with toluene (x2) and drying in vacuum desiccator (containing KOH) overnight gave a yellow oil (25b). The crude oil was dissolved in i PrOH (4.4 mL) and both 2-amino-3-nitro-4,5-dichloropyridine (190 mg, 0.752 mmol) and DIPEA (520 µl, 3.00 mmol) were added.
The solution was stirred at 50 °C for 4 h. On cooling a yellow precipitate formed which was filtered, washed with Et 2 O, dried in vacuo to yield the title compound as a yellow solid (165 mg, 65%). The filtrate was concentrated in vacuo to give 715 mg of an oily yellow solid.
Purification was accomplished by flash chromatography on silica gel (4 x 11) eluting with 4-(6-Chloro-2-(1,3-dimethyl-1H-pyrazol-4-yl -4-(4-(5-methyl-1,2,4-oxadiazol-3-yl)methylpiperazin-1-yl Butyl 4-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)piperazine-1-carboxylate (24d) To a solution of Boc-piperazine (217 mg, 1.16 mmol) and 3-(chloromethyl)-1-methyl-1H-1,2,4-triazole HCl salt (200 mg, 1.19 mmol) in CH 2 Cl 2 (8 mL) was added triethylamine (0.45 mL, 3.24 mmol). The reaction mixture was stirred at room temperature for 20 h and then at 50 °C for 18 h before being concentrated in vacuo. Purification of the crude product was accomplished by flash chromatography on silica gel to yield the title compound (290 mg, -4-(4-((1-methyl-1H-1,2,4-triazol-3-yl) 
3-((
2-Amino-5-chloro
tert-
5-Chloro
methyl)piperazin-1-yl)-3-nitropyridin-2amine (26d)
To a solution of tert-butyl 4-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)piperazine-1carboxylate (142 mg, 0.51 mmol) in CH 2 Cl 2 (30 mL) was added TFA (3.0 mL) and the solution was stirred at room temperature for 16 h. The reaction was concentrated in vacuo to give a yellow oil (25d). The crude oil was dissolved in i PrOH (6.3 mL) and both 2-amino-3nitro-4,5-dichloropyridine (100 mg, 0.48 mmol) and DIPEA (377 µl, 2.16 mmol) were added, and the reaction mixture was stirred at 50 °C for 4½ hr. On cooling a yellow precipitate S28 formed which was filtered, washed with ice cold i PrOH then Et 2 O, dried in vacuo to yield the title compound as a yellow solid (142 mg, 84%). 1 H-NMR (500 MHz, CDCl 3 ) 2.66 (app t, J = 4.7 Hz, 4H, CH 2 ), 3.21 (app t, J = 4.7 Hz, 4H, CH 2 ), 3.78 (s, 2H, CH 2 C), 3.98 (s, 3H, -2-(1,3-dimethyl-1H-pyrazol-4-yl)-7-(4-((1-methyl-1H-1,2,4-triazol-3- 
6-Chloro
yl)methyl)piperazin-1-yl)-3H-imidazo[4,5-b]pyridine (27d)
To a solution of 5-chloro-4-(4-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)piperazin-1-yl)-3nitropyridin-2-amine (45 mg, 0.128 mmol) and 1,3-dimethyl-1H-pyrazole-4-carbaldehyde 
tert-Butyl 4-(pyrimidin-5-ylmethyl)piperazine-1-carboxylate (24f)
To a solution of 1-Boc-piperazine (0.45 g, 2.40 mmol) in anhydrous dichloromethane (25 mL) was added 5-formylpyrimidine (0.260 g, 2.40 mmol) followed by sodium triacetoxyborohydride (0.600g, 2.76 mmol) and acetic acid (0.144 g, 2.40 mmol). The reaction mixture was stirred at room temperature for 6 h, and then diluted with chloroform (25 mL), washed with a 10% aqueous NaHCO 3 solution (2 x 40 mL), and brine (20 mL). The 
5-Chloro-3-nitro-4-(4-(pyrimidin-5-ylmethyl)piperazin-1-yl)pyridin-2-amine (26f)
A solution of tert-butyl 4-(pyrimidin-5-ylmethyl)piperazine-1-carboxylate (0.567 g, 2.03 mmol) in TFA (12 mL) and dichloromethane (17 mL) was stirred at room temperature for 2 h and 15 min. The solvents were then removed under reduced pressure and azeotroped with toluene. The resultant residue (25f) was dissolved in isopropanol (34 mL), and to this solution 4,5-dichloro-3-nitropyridin-2-amine (0.395 g, 1.90 mmol) was added followed by diisopropylethylamine (1.77 mL, 10.15 mmol). The reaction mixture was stirred at 45 o C for 18 h, it was then allowed to cool to room temperature and diluted with isopropanol (20 mL).
The yellow precipitate was collected by filtration, washed with isopropanol, diethyl ether, and dried (0.380 g, 54%). 1 H-NMR (500 MHz, DMSO-d 6 ) 2.50 (br s, obscured by solvent peak, piperazine N-CH), 3.06 (br s, 4H, piperazine N-CH), 3.59 (s, 2H, NCH 2 -pyrimidine), -2-(1,3-dimethyl-1H-pyrazol-4-yl)-7-(4-(pyrimidin-5-ylmethyl) piperazin-1-yl)-
6-Chloro
3H-imidazo[4,5-b]pyridine (27f)
To a mixture of 5-chloro-3-nitro-4-(4-(pyrimidin-5-ylmethyl)piperazin-1-yl)pyridin-2-amine (0.070 g, 0.20 mmol) and EtOH (3.5 mL) was added 1,3-dimethyl-1H-pyrazole-4carbaldehyde (0.027 g, 0.22 mmol) followed by a freshly prepared aqueous solution of Na 2 S 2 O 4 (1M; 0.80 mL, 0.80 mmol). The reaction mixture was stirred at 80 o C for 18 h, it was then allowed to cool to room temperature, and concentrated in vacuo. The resultant residue was absorbed on silica gel, placed on a 10 g isolute silica column which was first eluted with ethyl acetate / dichloromethane (v:v; 1:1), and then 4%, 6%, and 10% methanol in ethyl acetate. The product obtained was triturated with diethyl ether, the yellow precipitate was collected by filtration, and it was successively washed with diethyl ether (2 x 5 mL), water (4 x 3 mL), diethyl ether (3 x4 mL), then dried in vacuo over P 2 O 5 (0.013 g, 15%). 
tert-Butyl 4-(pyrazin-2-ylmethyl)piperazine-1-carboxylate (24g)
To a solution of 1-Boc-piperazine (0.298 g, 1.60 mmol) in anhydrous dichloromethane (22 mL) was added pyrazine-2-carbaldehyde (0.173 g, 1.60 mmol) followed by sodium triacetoxyborohydride (0.392g, 1.76 mmol) and acetic acid (0.096 g, 1.6 mmol). The reaction mixture was stirred at room temperature for 6.5 h; it was then was diluted with dichloromethane (25 mL) and washed with a 10% aqueous NaHCO 3 solution (2 x 35 mL), and brine (30 mL). The organic layer was dried (MgSO 4 ), and concentrated in vacuo to afford the title compound as a yellow oily residue (0.403 g, 91%). 
5-Chloro-3-nitro-4-(4-(pyrazin-2-ylmethyl)piperazin-1-yl)pyridin-2-amine (26g)
A solution of tert-butyl 4-(pyrazin-2-ylmethyl)piperazine-1-carboxylate (0.336 g, 1.21 mmol) in TFA (7 mL) and dichloromethane (10 mL) was stirred at room temperature for 2 h. The solvents were then removed under reduced pressure and azeotroped with toluene. The resultant residue (25g) was dissolved in isopropanol (20 mL), and to this solution 4,5dichloro-3-nitropyridin-2-amine (0.235 g, 1.13 mmol) was added followed by diisopropylethylamine (1.07 mL, 6.0 mmol). The reaction mixture was stirred at 45 o C for 20 h; it was then allowed to cool to room temperature and diluted with isopropanol (10 mL). The yellow precipitate was collected by filtration, washed with isopropanol, diethyl ether, and -2-(1,3-dimethyl-1H-pyrazol-4-yl)-7-(4-(pyrazin-2-ylmethyl) piperazin-1-yl)-3H-
6-Chloro
imidazo[4,5-b]pyridine (27g)
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